Recent trials in sarcoma sought to determine the impact of neoadjuvant therapies and histologic/genomically specific treatments. Valerie Grignol, MD, Gabriel R. Tinoco Suarez, MD, and Alessandro Gronchi, MD, FSSO, discuss the following recent trials will. The EORTC-62902:STRASS trial evaluated the impact of neoadjuvant radiotherapy for retroperitoneal sarcoma on abdominal recurrence-free survival. A study by the Italian, Spanish, French and Polish Sarcoma groups sought to determine if histology-tailored neoadjuvant chemotherapy was superior to standard anthracycline plus ifosfamide for high-risk extremity and trunk soft tissue sarcoma for disease-free and overall survival. The NAVIGATOR study evaluated the PDGFRA inhibitor avapritinib and its activity in D842V-mutant gastrointestinal stromal tumors. Lastly the INVICTUS study evaluated the impact of further line therapy ripretinib, a switch-control tyrosine kinase inhibitor, on progression-free survival in advanced gastrointestinal stromal tumors.

Valerie Grignol, MD – Member, SSO Sarcoma Disease Site Work Group, Assistant Professor of Surgery, The Ohio State University

Gabriel R. Tinoco Suarez, MD – Medical Oncologist and Clinical Assistant Professor – Division of Medical Oncology at The Ohio State University

Alessandro Gronchi, MD, FSSO – Chair Sarcoma Service – Department of Surgery; Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)